TransMedics Group earnings release, May 5, 2026

TransMedics Group, Inc. (TMDX) · Form 8-K, Item 2.02 · Filed · SEC filing

TransMedics Reports First Quarter 2026 Financial Results

Andover, Mass. – May 5, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2026.

Recent Highlights

▪ Total revenue of $173.9 million in the first quarter of 2026, a 21% increase compared to the first quarter of

2025

▪ Net income of $7.3 million or $0.20 per fully diluted share in the first quarter of 2026

▪ Adjusted net income of $10.9 million or $0.30 per fully diluted share in the first quarter of 2026

▪ Reiterates full year 2026 revenue guidance to be in the range of $727 million to $757 million

▪ Owned 22 aircraft as of March 31, 2026

▪ Hosted annual symposium at the International Society of Heart and Lung Transplantation (ISHLT) 46 th

Annual Meeting & Scientific Session in Toronto; unveiled new Controlled Hypothermic Organ Preservation System (“CHOPS”) aimed at facilitating enrollment in control arms of OCS ENHANCE Heart Part B and OCS DENOVO Lung clinical trials

▪ Entered into definitive agreement to invest in PAD Aviation, a premier Germany-based private aviation operator, with intent to create the first dedicated European transplant logistic network

“We are pleased with our first quarter results and see 2026 as another critical period for TransMedics as we deliver on several critical growth catalysts for our business,” said Waleed Hassanein, MD, President and Chief Executive Officer. “We are laser focused on executing our multi-pronged growth strategy by accelerating ENHANCE heart and DENOVO lung programs in the U.S., launching our NOP model in Europe, and advancing our OCS Kidney program. We believe these initiatives will position us well to drive continued growth and expand access to life-saving transplants for patients globally.”

A summary of first quarter financial results is as follows (dollars in thousands except per share):

(1)

Adjusted income from operations, adjusted operating margin and adjusted diluted net income per share represent non-GAAP financial measures. For a reconciliation of GAAP to Non-GAAP items, please see the tables attached to this press release.

First Quarter 2026 Financial Results

Total revenue for the first quarter of 2026 was $173.9 million, a 21% increase compared to $143.5 million in the first quarter of 2025. The increase was due primarily to the increase in utilization of the Organ Care System (“OCS”), primarily in Liver and Heart through the National OCS Program (“NOP”) as well as additional revenue generated by TransMedics logistics services.

Gross margin for the first quarter of 2026 was 58%, compared to 61% in the first quarter of 2025. Gross margin was impacted primarily by investments to support growth and scale, together with higher supply chain and operating costs compared to the prior year.

Operating expenses for the first quarter of 2026 were $87.9 million compared to $60.8 million in the first quarter of 2025. The increase in operating expenses was driven primarily by increased research and development investment as well as investment throughout the organization to support the growth of the company. First quarter operating expenses in 2026 included $9.6 million of stock compensation expense compared to $8.7 million of stock compensation expense in the first quarter of 2025.

Income from operations in the first quarter of 2026 was $13.3 million, compared to operating income of $27.4 million in the first quarter of 2025. Adjusted income from operations in the first quarter of 2026 was $18.1 million compared to adjusted income from operations of $29.8 million in the first quarter of 2025.

Net income in the first quarter of 2026 was $7.3 million, or $0.20 per diluted share, compared to net income of $25.7 million, or $0.70 per diluted share, in the first quarter of 2025. Adjusted net income in the first quarter of 2026 was $10.9 million, or $0.30 per diluted share compared to adjusted net income of $27.4 million, or $0.74 per diluted share, in the first quarter of 2025.

Cash was $461.7 million as of March 31, 2026

2026 Financial Outlook

TransMedics is reiterating its full year 2026 revenue guidance to be in the range of $727 million to $757 million, which represents 20% to 25% growth compared to the company’s prior year revenue.

Webcast and Conference Call Details

The TransMedics management team will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT on Tuesday, May 5, 2026. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 9254082. A live and archived webcast of the event and the company’s slide presentation with information on first quarter 2026 financial results will be available on the “Investors” section of the TransMedics website at www.transmedics.com.

About TransMedics Group, Inc.

TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Financial statements

Income Statement

Three Months Ended March 31, — A summary of first quarter financial results is as follows (dollars in thousands except per share):

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025% Change
Revenue173,933143,53721.0%
Income from operations13,29727,443-52.0%
Operating margin %7.6%19.1%-1147bps
Adjusted income from operations(1)18,10929,801-39.0%
Adjusted operating margin %(1)10.4%20.7%-1030bps
Diluted net income per share0.20.7-71.0%
Adjusted diluted net income per share(1)0.30.74-59.0%

Income Statement

Three Months Ended March 31, — TransMedics Group, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) (unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenue:Net product revenue107,97288,234
Revenue:Service revenue65,96155,303
Revenue:Total revenue173,933143,537
Cost of revenue:Cost of net product revenue24,30816,312
Cost of revenue:Cost of service revenue48,46438,997
Cost of revenue:Total cost of revenue72,77255,309
Cost of revenue:Gross profit101,16188,228
Cost of revenue:Gross margin58.0%61
Operating expenses:Research, development and clinical trials24,87917,160
Operating expenses:Selling, general and administrative62,98543,625
Operating expenses:Total operating expenses87,86460,785
Operating expenses:Income from operations13,29727,443
Other income (expense):Interest expense-7,170-3,461
Other income (expense):Interest income and other income (expense), net2,3582,694
Other income (expense):Total other expense, net-4,812-767
Other income (expense):Income before income taxes8,48526,676
Other income (expense):Provision for income taxes-1,170-994
Other income (expense):Net income7,31525,682
Net income per share:Basic0.210.76
Net income per share:Diluted0.20.7
Weighted average common shares outstanding:Basic34,384,20733,721,603
Weighted average common shares outstanding:Diluted36,194,02339,914,487

Income Statement

Three Months Ended March 31, 2026 — (unaudited) (in thousands)

Three Months Ended March 31, 2026 – Income from OperationsThree Months Ended March 31, 2026 – Operating Margin %Three Months Ended March 31, 2026 – Net IncomeThree Months Ended March 31, 2026 – Diluted Net Income per Common Share
Reported13,2977.6%7,3150.2
Non-GAAP adjustments:Incremental amortization of acquired intangible assets(1)1,8981.1%1,4180.04
Non-GAAP adjustments:Transaction-related costs(2)2,7071.6%2,0230.06
Non-GAAP adjustments:Headquarters relocation costs(3)2070.1%1550
Non-GAAP adjustments:Adjusted18,10910.4%10,9110.3

Income Statement

Three Months Ended March 31, 2025 — (unaudited)

Three Months Ended March 31, 2025 – Income from OperationsThree Months Ended March 31, 2025 – Operating Margin %Three Months Ended March 31, 2025 – Net IncomeThree Months Ended March 31, 2025 – Diluted Net Income per Common Share
Reported27,44319.1%25,6820.7
Non-GAAP adjustments:Legal matters(4)2,3581.6%1,7590.04
Non-GAAP adjustments:Adjusted29,80120.7%27,4410.74

Balance Sheet

December 31, — TransMedics Group, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited)

March 31, – 2026December 31, – 2025
Current assets:Cash461,739488,366
Current assets:Accounts receivable90,72784,282
Current assets:Inventory49,89048,881
Current assets:Prepaid expenses and other current assets16,92416,254
Current assets:Total current assets619,280637,783
Current assets:Property, plant and equipment, net361,571327,656
Current assets:Finance lease right-of-use assets, net334,545
Current assets:Operating lease right-of-use assets, net4,8585,155
Current assets:Deferred tax assets82,47683,543
Current assets:Restricted cash18,438500
Current assets:Goodwill11,54911,549
Current assets:Acquired intangible assets, net1,948
Current assets:Other non-current assets2,103239
Current assets:Total assets1,434,8201,068,373
Current liabilities:Accounts payable11,15110,350
Current liabilities:Accrued expenses and other current liabilities59,31662,740
Current liabilities:Current portion of long-term debt15,00010,000
Current liabilities:Deferred revenue2,9452,905
Current liabilities:Operating lease liabilities3,5083,310
Current liabilities:Total current liabilities91,92089,305
Current liabilities:Convertible senior notes, net453,530452,804
Current liabilities:Long-term debt, net44,66549,587
Current liabilities:Finance lease liability343,829
Current liabilities:Operating lease liabilities, net of current portion2,8833,577
Current liabilities:Other long-term liabilities3,986
Current liabilities:Total liabilities940,813595,273
Current liabilities:Total stockholders’ equity494,007473,100
Current liabilities:Total liabilities and stockholders’ equity1,434,8201,068,373
Full release

Forward-Looking Statements... (truncated)r this purpose, all statements other than statements of historical facts are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “could,” “target,” “predict,” “seek” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: the fluctuation of our financial results from quarter to quarter; our ability to attract, train and retain key personnel; our dependence on the success of the OCS; our ability to expand access to the OCS through our NOP; our ability to improve the OCS platform, including by developing the next generation of the OCS products or expanding into new indications and the development, and potential commercialization of our OCS Kidney device; the timing or results of clinical trials for the OCS, including pre- and post-approval studies, or other product candidates, including CHOPS; our ability to sustain profitability; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; that we have identified a material weakness in our internal control over financial reporting, and that we may identify additional material weaknesses in the future; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration (the “FDA”) or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including recently enacted or potential future legislation or administrative actions affecting or reforming the U.S. healthcare system, Organ Procurement and Transplantation Network, or the FDA; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our transplant logistics capabilities to support our NOP to reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration, or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology, or IT, infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products or services infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the impact of a shutdown of the U.S. government; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreements to which we will remain subject until maturity; the impact of any product recalls or improper use of our products; our international expansion plans and the costs related thereto; our estimates regarding revenue, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the “SEC”). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Use of Non-GAAP Financial Measures... (truncated) operations, adjusted operating margin, adjusted net income, and adjusted diluted net income per common share. These non-GAAP financial measures are not calculated in accordance with GAAP, are not a substitute for, and should be considered supplemental to, GAAP financial measures. Our definitions of these non-GAAP measures may differ from similarly titled measures used by other companies, which may limit their usefulness for comparative purposes.

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe the presentation of these measures is useful to both management and investors as they provide meaningful supplemental information with respect to our core operational performance and allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

To calculate adjusted income from operations, adjusted operating margin, adjusted net income and adjusted diluted net income per common share, we exclude certain charges (credits) from GAAP income from operations and GAAP net income, such as transaction-related costs, incremental amortization of intangible assets, headquarters relocation costs and legal matters. Amounts are presented after-tax using the company's statutory tax rate unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate.”

Investor Contact:

Brian Johnston

332-895-3222

Investors@transmedics.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · TransMedics Group earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.